Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CTI BioPharma Corp. (Nasdaq: CTIC) announced its participation in two key investor conferences in April 2023, aimed at discussing its novel targeted therapies for blood-related cancers. The company will engage in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 3:45 p.m. ET, and will present at the Stifel 2023 Targeted Oncology Days on April 26, 2023, at 1:00 p.m. ET. Live and archived webcasts can be accessed through the CTI BioPharma website. CTI BioPharma is also noted for its FDA-approved product, VONJO® (pacritinib), which targets myelofibrosis patients with low platelet counts.
CTI BioPharma Corp. (Nasdaq: CTIC) announced on April 10, 2023, that its Compensation Committee granted equity inducement awards to two new employees. This was done under Nasdaq Listing Rule 5635(c)(4) and outside of the company's Amended and Restated 2017 Equity Incentive Plan.
The awards totaled options for 36,000 shares of CTIC common stock, with an exercise price equal to the closing price on each grant date. The options will vest over four years, contingent on continued employment, and are valid for a ten-year term.
CTI BioPharma focuses on targeted therapies for blood-related cancers and has one FDA-approved product, VONJO (pacritinib), aimed at treating patients with specific myelofibrosis conditions.